The latest set of opinions from advisors to the European Medicines Agency has seen two new medicines recommended for approval. The agency’s Committee for Human Medicinal Products (CHMP) has issued a positive recommendation on Opsumit (macitentan), Actelion’s new treatment for pulmonary arterial hypertension. The drug, which was approved by the US Food and Drug Administration earlier this month, is the follow-up to the Swiss biotech’s blockbuster Tracleer (bosentan), which goes off-patent in 2015.
Help employers find you! Check out all the jobs and post your resume.
